Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Comment by bligickaon Feb 24, 2021 4:52pm
84 Views
Post# 32650982

RE:Single dose of Johnson & Johnson vaccine is 66% effective !!

RE:Single dose of Johnson & Johnson vaccine is 66% effective !!Johnson & Johnson's single-dose vaccine is 66 per cent effective at protecting against COVID-19....that's great example of a late comer to market that has managed to differentiate their product from the others even though it's only 66% effective......... Too bad Vaxil can't even get to clinical trials after huge failure to produce protective antibodies duing USAMRIID experiment ...shame, first Merck and now Vaxil ....at least they have their 10 year old cancer orphan status drug ......I guess that's all we got at this point .....so what is the status of iMmucin anyways ??? Are they allowed to sell it or trial it ???
<< Previous
Bullboard Posts
Next >>